Loading...
XLON
POLB
Market cap26mUSD
Jul 29, Last price  
2.65GBP
1D
-5.36%
1Q
-19.70%
IPO
-75.06%
Name

Poolbeg Pharma PLC

Chart & Performance

D1W1MN
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-4m
L-16.11%
-2,336,000-4,686,000-3,931,000
CFO
-4m
L-11.93%
-2,146,000-4,368,000-3,847,000

Profile

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class intranasally administered RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro­ and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
IPO date
Jul 19, 2021
Employees
12
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFY
2023‑122022‑122021‑12
Income
Revenues
Cost of revenue
5,079
5,290
Unusual Expense (Income)
NOPBT
(5,079)
(5,290)
NOPBT Margin
Operating Taxes
(574)
(91)
Tax Rate
NOPAT
(4,505)
(5,199)
Net income
(3,931)
-16.11%
(4,686)
100.60%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(12,171)
(16,193)
Cash flow
Cash from operating activities
(3,847)
(4,368)
CAPEX
(597)
Cash from investing activities
359
(388)
Cash from financing activities
FCF
(4,898)
(5,131)
Balance
Cash
12,171
16,193
Long term investments
Excess cash
12,171
16,193
Stockholders' equity
(10,113)
(6,922)
Invested Capital
24,555
25,199
ROIC
ROCE
EV
Common stock shares outstanding
500
500,000
Price
Market cap
EV
EBITDA
(5,053)
(5,264)
EV/EBITDA
Interest
Interest/NOPBT